• Genomic Vision technology has demonstrated high accuracy for the quantitative analysis of genomic events.
• This evaluation paves the way for the implementation of standardized cell characterization methods
Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a biotechnology company listed on Euronext developing products and services dedicated to the analysis and control of genome modifications, is pleased to announce the success evaluation of its DNA molecular combing technology by the US National Institute of Standards and Technology (NIST). The evaluation confirmed the high precision of the technology for the quantitative analysis of genomic events at 10 kilobases or greater.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]